Caplyta, now FDA-approved as an adjunctive therapy for major depressive disorder, offers rapid relief and a favorable safety profile for patients. Learn more from Suresh Durgam, MD, the primary investigator.
Suresh Durgam, MD
Advertisement
Dr Durgam is the executive vice president and the chief medical officer of Intra-Cellular Therapies Inc, a Johnson & Johnson company. He is also the Study 501 and Study 502 primary investigator.
Articles by Suresh Durgam, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
Innovation in Schizophrenia Treatment: Evenamide Research With Anthony Grace, PhD
2
Let’s Retire Haloperidol
3
Hyperbaric Oxygen Therapy: An Innovative PTSD Treatment for Veterans
4
How Would ChatGPT Spend One Day as a Human?
5
